The Legal Rights of Religious Refugees in the Refugee-Cities of Early Modern Germany

Nowhere in early modern Europe (fifteenth to eighteenth centuries) did religious refugees enjoy more special legal protections than they did in the so-called ‘refugee-cities’ (Exulantenstädte) of Germany. These were new cities founded, mostly in the seventeenth century, by German princes with the express intention of attracting religious refugees to settle them. Offering two case studies, of Neuhanau and Neuwied, this article examines the legal provisions that extended personal, economic, civil and religious rights to the refugees who settled them. The article shows that these rights reflected the needs and desires of refugees as well as the agendas of early modern princes. It also shows why, to achieve the goals of both parties, it became standard practice to combine the refugees’ special rights with separate urban status for their settlements

An ecological approach to problems of Dark Energy, Dark Matter, MOND and Neutrinos

Modern astronomical data on galaxy and cosmological scales have revealed powerfully the existence of certain dark sectors of fundamental physics, i.e., existence of particles and fields outside the standard models and inaccessible by current experiments. Various approaches are taken to modify/extend the standard models. Generic theories introduce multiple de-coupled fields A, B, C, each responsible for the effects of DM (cold supersymmetric particles), DE (Dark Energy) effect, and MG (Modified Gravity) effect respectively. Some theories use adopt vanilla combinations like AB, BC, or CA, and assume A, B, C belong to decoupled sectors of physics. MOND-like MG and Cold DM are often taken as opposite frameworks, e.g. in the debate around the Bullet Cluster. Here we argue that these ad hoc divisions of sectors miss important clues from the data. The data actually suggest that the physics of all dark sectors is likely linked together by a self-interacting oscillating field, which governs a chameleon-like dark fluid, appearing as DM, DE and MG in different settings. It is timely to consider an interdisciplinary approach across all semantic boundaries of dark sectors, treating the dark stress as one identity, hence accounts for several "coincidences" naturally.Comment: 12p, Proceedings to the 6-th Int. Conf. of Gravitation and Cosmology. Neutrino section expande

Serum Penicillin G Levels Are Lower Than Expected in Adults within Two Weeks of Administration of 1.2 Million Units

When introduced in the 1950s, benzathine penicillin G (BPG) was shown to be effective in eradicating group A beta-hemolytic streptococcus (GAS) for at least 3 weeks after administration. Several studies since the 1990s suggest that at 3–4 weeks serum penicillin G levels are less than adequate (below MIC90 of 0.016 µg/ml). We studied these levels for 4 weeks after the recommended dose of BPG in military recruits, for whom it is used as prophylaxis against GAS. The 329 subjects (mean age 20 years) each received 1.2 million units BPG IM and gave sera 1 day post injection and twice more at staggered time points over 4 weeks. Serum penicillin G levels were measured by liquid chromatography/tandem mass spectometry. The half-life of serum penicillin G was 4.1 days. By day 11, mean levels were <0.02 µg/ml, and by day 15<0.01 µg/ml. Levels in more than 50% of the subjects were below 0.02 µg/ml on day 9, and <.01 µg/ml on day 16. There was no demonstrable effect of subject body-surface area nor of the four different lots of BPG used. These data indicate that in healthy young adults serum penicillin G levels become less than protective <2½ weeks after injection of 1.2 million units of BPG. The findings require serious consideration in future medical and public health recommendations for treatment and prophylaxis of GAS upper respiratory tract infections

Database analysis of children and adolescents with Bipolar Disorder consuming a micronutrient formula

<p>Abstract</p> <p>Background</p> <p>Eleven previous reports have shown potential benefit of a 36-ingredient micronutrient formula (known as EMPowerplus) for the treatment of psychiatric symptoms. The current study asked whether children (7-18 years) with pediatric bipolar disorder (PBD) benefited from this same micronutrient formula; the impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on their response was also evaluated.</p> <p>Methods</p> <p>Data were available from an existing database for 120 children whose parents reported a diagnosis of PBD; 79% were taking psychiatric medications that are used to treat mood disorders; 24% were also reported as ADHD. Using Last Observation Carried Forward (LOCF), data were analyzed from 3 to 6 months of micronutrient use.</p> <p>Results</p> <p>At LOCF, mean symptom severity of bipolar symptoms was 46% lower than baseline (effect size (ES) = 0.78) (<it>p </it>< 0.001). In terms of responder status, 46% experienced >50% improvement at LOCF, with 38% still taking psychiatric medication (52% drop from baseline) but at much lower levels (74% reduction in number of medications being used from baseline). The results were similar for those with both ADHD and PBD: a 43% decline in PBD symptoms (ES = 0.72) and 40% in ADHD symptoms (ES = 0.62). An alternative sample of children with just ADHD symptoms (n = 41) showed a 47% reduction in symptoms from baseline to LOCF (ES = 1.04). The duration of reductions in symptom severity suggests that benefits were not attributable to placebo/expectancy effects. Similar findings were found for younger and older children and for both sexes.</p> <p>Conclusions</p> <p>The data are limited by the open label nature of the study, the lack of a control group, and the inherent self-selection bias. While these data cannot establish efficacy, the results are consistent with a growing body of research suggesting that micronutrients appear to have therapeutic benefit for children with PBD with or without ADHD in the absence of significant side effects and may allow for a reduction in psychiatric medications while improving symptoms. The consistent reporting of positive changes across multiple sites and countries are substantial enough to warrant a call for randomized clinical trials using micronutrients.</p

Challenges to the development of antigen-specific breast cancer vaccines

Continued progress in the development of antigen-specific breast cancer vaccines depends on the identification of appropriate target antigens, the establishment of effective immunization strategies, and the ability to circumvent immune escape mechanisms. Methods such as T cell epitope cloning and serological expression cloning (SEREX) have led to the identification of a number target antigens expressed in breast cancer. Improved immunization strategies, such as using dendritic cells to present tumor-associated antigens to T lymphocytes, have been shown to induce antigen-specific T cell responses in vivo and, in some cases, objective clinical responses. An outcome of successful tumor immunity is the evolution of antigen-loss tumor variants. The development of a polyvalent breast cancer vaccine, directed against a panel of tumor-associated antigens, may counteract this form of immune escape